IL17B抗体;IL17B Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Rat pancreas tissue lysate, Primary antibody: P13342(IL17B Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P13342(IL17B Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Interleukin-17B (IL-17B) is a member of the IL-17 cytokine family, which plays roles in inflammatory and immune responses. Discovered in 2000. IL-17B binds to the IL-17RB receptor, activating downstream signaling pathways like NF-κB and MAPK, and is implicated in autoimmune diseases, cancer, and tissue inflammation. Its overexpression in certain cancers (e.g., pancreatic, gastric) correlates with tumor progression, angiogenesis, and immune evasion, while in conditions like rheumatoid arthritis, it may drive pathogenic inflammation.

IL-17B antibodies are therapeutic or research tools designed to neutralize IL-17B activity. These monoclonal antibodies typically block IL-17B binding to IL-17RB, disrupting pro-inflammatory or pro-tumorigenic signaling. Preclinical studies show promise in reducing tumor growth and inflammation in animal models, suggesting potential for oncology and autoimmune disease applications. However, the biology of IL-17B remains less characterized compared to other IL-17 family members (e.g., IL-17A), creating knowledge gaps in its precise mechanisms and receptor interactions. Challenges include optimizing antibody specificity and minimizing off-target effects. Current research focuses on elucidating IL-17B's dual roles in immunity and pathology to refine therapeutic strategies. Clinical data are limited, underscoring the need for further investigation into safety and efficacy.